Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WuXi PharmaTech Disappointed With Charles River Breakup; Faces Toxicology Field Alone

This article was originally published in The Pink Sheet Daily

Executive Summary

WuXi expects to have a full service toxicology operation in China in the next five years, which would have been accelerated by a merger with Charles River. By 2015, China is expected to gain more of the global toxicology service market projected to reach $150 million to $200 million.
Advertisement

Related Content

Charles River Abandons WuXi PharmaTech Just Days Before Crucial Shareholder Votes On Planned Merger
Charles River Abandons WuXi PharmaTech Just Days Before Crucial Shareholder Votes On Planned Merger
China Anticipates Speeding Up R&D By Joining OECD As Observer - DIA China Conference
China's Wuxi PharmaTech Signs New Agreement On Toxicology Studies Training And Services With J&J Unit
WuXi Apptec Plots Future, But Is It Overreaching?
Covance, WuXi Abandon Plans To Create Joint Drug Testing Facility In China

Topics

Advertisement
UsernamePublicRestriction

Register

PS071109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel